Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study

被引:65
作者
Danilowicz, Karina [1 ]
Bruno, Oscar Domingo [1 ]
Manavela, Marcos [1 ]
Gomez, Reynaldo Manuel [1 ,2 ]
Barkan, Ariel [3 ]
机构
[1] Hosp Clin Buenos Aires, Div Endocrinol, Buenos Aires, Argentina
[2] Diagnost Med SRL, Buenos Aires, DF, Argentina
[3] Univ Michigan, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA
关键词
hypopituitarism; cortisol replacement; growth hormone deficiency;
D O I
10.1007/s11102-008-0126-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Hyporituitarism in adults is known to be associated with deleterious effects on body composition, lipid profile and quality of life (QoL). This was attributed to GH deficiency. The potential role of glucocorticoid overreplacement had never been investigated. Objective To investigate whether reduction in glucocorticoid replacement dose to more physiological one could ameliorate the "AO-GHD"-attributed symptomatology in patients with hypopituitarism. Design Eleven patients with panhypopituitarism taking 20-30 mg/day of hydrocortisone, but on no GH replacement were switched to 10-15 mg of hydrocortisone daily. Both basally and 6-12 months later, their body mass index, body composition by dual-energy X-ray absorptiometry, lipid profile, and the score of quality of life, QOL-AGHDA were measured. Results Within 6-12 months of lower hydrocortisone dose, subjects lost an average of 7.1 kg of total body fat and 4.1 kg of abdominal fat. No changes were seen in lean body mass, bone mineral content and HOMA-IR. Plasma total cholesterol and triglyceride concentrations decreased significantly (< 0.05) and the QoL improved (P = 0.018). Conclusions Our pilot study suggests that decreasing the glucocorticoid replacement dose to similar to 15 mg/day is beneficial in terms of patients' body composition, lipid profile and quality of life.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 28 条
[1]   Human growth hormone replacement in adult hypopituitary patients: Long-term effects on body composition and lipid status - 3-year results from the HypoCCS database [J].
Attanasio, AF ;
Bates, PC ;
Ho, KKY ;
Webb, SM ;
Ross, RJ ;
Strasburger, CJ ;
Bouillon, R ;
Crowe, B ;
Selander, K ;
Valle, D ;
Lamberts, SWJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04) :1600-1606
[2]   ABNORMAL BODY-COMPOSITION AND REDUCED BONE MASS IN GROWTH-HORMONE DEFICIENT HYPOPITUITARY ADULTS [J].
BESHYAH, SA ;
FREEMANTLE, C ;
THOMAS, E ;
RUTHERFORD, O ;
PAGE, B ;
MURPHY, M ;
JOHNSTON, DG .
CLINICAL ENDOCRINOLOGY, 1995, 42 (02) :179-189
[3]   ENDOCRINE AND METABOLIC DISEASES - ADRENAL DISEASES [J].
BESSER, GM ;
JEFFCOATE, WJ .
BRITISH MEDICAL JOURNAL, 1976, 1 (6007) :448-451
[4]   Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy [J].
Christopher, M ;
Hew, FL ;
Oakley, M ;
Rantzau, C ;
Alford, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1668-1681
[5]   Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency [J].
Colao, A ;
Di Somma, C ;
Rota, F ;
Pivonello, R ;
Savanelli, MC ;
Spiezia, S ;
Lombardi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :2056-2062
[6]   The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults [J].
Cuneo, RC ;
Judd, S ;
Wallace, JD ;
Perry-Keene, D ;
Burger, H ;
Lim-Tio, S ;
Strauss, B ;
Stockigt, J ;
Topliss, D ;
Alford, F ;
Hew, L ;
Bode, H ;
Conway, A ;
Handelsman, D ;
Dunn, S ;
Boyages, S ;
Cheung, NW ;
Hurley, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :107-116
[7]  
DUNNE FP, 1995, CLIN ENDOCRINOL, V43, P623, DOI 10.1111/j.1365-2265.1995.tb02928.x
[8]   Supraphysiological growth hormone:: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults [J].
Ehrnborg, C ;
Ellegård, L ;
Bosaeus, I ;
Bengtsson, BÅ ;
Rosén, T .
CLINICAL ENDOCRINOLOGY, 2005, 62 (04) :449-457
[9]  
ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P1698
[10]   The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients [J].
Filipsson, Helena ;
Monson, John P. ;
Koltowska-Haggstrom, Maria ;
Mattsson, Anders ;
Johannsson, Gudmundur .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (10) :3954-3961